IMODI published its first newsletter on its new website
20 September 2016
Show all

The European project RARENET acquires MBioLIMS®

Logo RARENET Complet
For the creation of collections of biological samples associated with clinical data, the European project RARENET is adopting the MBioLIMS® software from Modul-Bio for 13 hospitals in France and Germany.
RARENET aims to provide optimal care for patients suffering from rare autoimmune and/or oro-dental diseases as part of a dynamic information, training, expertise and analysis approach.
This cross-border cooperation project, co-financed by the European Regional Development Fund (ERDF) of the European Union within the framework of the INTERREG V Upper Rhine programme and coordinated by the University Hospitals of Strasbourg and Strasbourg University, facilitates the diagnosis and a better understanding of these diseases by creating collections of samples and the related clinical data.
the MBioLIMS® software program to standardise management of a large volume of patient clinical data by means of highly configurable forms (eCRF)
RARENET has thus selected the MBioLIMS® software program to standardise management of a large volume of patient clinical data by means of highly configurable forms (eCRF) for pathologies, targeting rare diseases such as:
  • Oligodontia
  • Lupus
  • Scleroderma
  • Oligodontia
  • Lupus
  • Scleroderma
The software also manages the patient cohorts for each of these diseases with secure management of the collections of biological samples taken in the 13 hospitals. Together with the clinical data and analyses, these samples will enable the predictive markers of these diseases to be identified.

About RARENET

RARENET is a cross-border project supported by the European Union within the framework of the Interreg V programme. Coordinated by professors Agnès Bloch-Zupan and Anne-Sophie Korganow (Unistra and HUS), RARENET is the fruit of cooperation between over thirty French, German and Swiss partners: universities, hospitals, reference centres, research labs, health sector stakeholders and patient organisations.